This application relates to novel compounds of formula (I) (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and the use of the compounds of formula (I) as thrombin inhibitors.
A unified protocol for the construction of 3-(2-bromoethyl)benzofurans and 2-(benzofuran-3-yl)ethylamines from bis[(trimethylsilyl)oxy]cyclobutene has been developed. This mild and facile strategy was applied for the synthesis of a series of 5-HT serotonin receptor agonists, underlining its potential for the syntheses of bioactive compounds and natural products.
Novel farnesyl protein transferase inhibitors as antitumor agents
申请人:Schering Corporation
公开号:US20040122018A1
公开(公告)日:2004-06-24
Disclosed are novel tricyclic compounds represented by the formula (1.0):
1
and a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
Provided are methods of producing refined silane compounds comprising providing a starting composition comprising a silane ester and an acidic halide and contacting the starting composition with an alkali metal salt selected from the group consisting of alkali metal salts derived from amides, imides, oxazolidinones, amines, sulfonamides, and combinations of two or more thereof.
Method and compositions for identifying anti-HIV therapeutic compounds
申请人:Arimilli N. Murty
公开号:US20050239054A1
公开(公告)日:2005-10-27
Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.